A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

Giselle L Saulnier Sholler Dan G Duda Genevieve Bergendahl David Ebb Matija Snuderl Theodore W Laetsch Jennifer Michlitsch Derek Hanson Michael S Isakoff Kevin Bielamowicz Jacqueline M Kraveka William S Ferguson Peter Carmeliet A De Deene Lore Gijsen Rakesh K Jain

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

TB-403 was safe and well tolerated at all dose levels. No MTD was reached. The results look encouraging and therefore warrant further evaluation of efficacy in pediatric subjects with medulloblastoma.

Keyphrases

mycobacterium tuberculosis
acute lymphoblastic leukemia
acute myeloid leukemia
study protocol
phase iii
multiple myeloma
diffuse large b cell lymphoma
clinical trial
hodgkin lymphoma
phase ii
young adults
open label